Dr. Isabella Caniggia Joins Miraculins Inc. Scientific Advisory Board

WINNIPEG, MANITOBA--(Marketwire - February 12, 2009) - Miraculins Inc. (TSX VENTURE: MOM), a medical diagnostic company focused on developing and commercializing diagnostic tests for unmet clinical needs, is pleased to announce that Dr. Isabella Caniggia has joined its Scientific Advisory Board. Dr. Caniggia is an internationally recognized preeclampsia researcher and physician at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in Toronto.

“Dr. Caniggia’s dedication to reducing the suffering of women who develop preeclampsia, after her family was personally touched by this devastating disease, is deeply inspiring and I am very proud to have Isabella join our SAB”, said Christopher J. Moreau, president and CEO of Miraculins Inc. “Her leading research on hypoxic conditions of the placenta has advanced the field for early preeclampsia detection methods and includes the discovery of endoglin, which has consistently been the top performing biomarker for preeclampsia in a number of independent clinical studies.”

“I am pleased to join Miraculins in working towards the goal of better outcomes for women with preeclampsia and I am encouraged that our work will lead to improved early diagnostic tools so that physicians will no longer have to rely on symptoms alone to determine if a patient is at risk for developing preeclampsia”, commented Dr. Caniggia.

In addition to her position of Scientist at the Samuel Lunenfeld Research Institute and Associate Professor of Obstetrics and Gynaecology at the University of Toronto, Dr. Isabella Caniggia is a certified medical practitioner and surgeon with full registration from the Medical Counsel of Siena. Widely published in scientific journals and with over 100 invited presentations, Dr. Caniggia also serves as a reviewer for a number of leading peer-reviewed scientific journals and has been the recipient of numerous academic honours, grants and awards, including a number from the respected Canadian Institute of Health Research (CIHR). Dr. Caniggia’s laboratory is at the forefront of research into the molecular signatures of preeclampsia and she is the inventor of Miraculins’ promising technology in this area.

About Miraculins Inc.

Miraculins is a medical diagnostic development company focused on non-invasive tests for unmet clinical needs. Miraculins is bridging the gap between commercially available diagnostic tests and research conducted at leading research institutions around the world.

Caution Regarding Forward-Looking Information

Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, “forward-looking statements”). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “will,” “may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.

These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Miraculins’ early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers’ willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Miraculins’ filings with Canadian securities regulatory authorities, as well as Miraculins’ ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release. Miraculins cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Miraculins’ forward-looking statements to make decisions with respect to Miraculins investors and others should carefully consider the foregoing factors and other uncertainties and potential events.

These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Miraculins cannot provide assurance that actual results will be consistent with these forward-looking statements. Miraculins undertakes no obligation to update or revise any forward-looking statement.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.